Natco Pharma rights issue: ₹1,300 crore plan in 2026

Board clears fundraise via rights issue

Natco Pharma’s board has approved a rights issue of equity shares to existing shareholders to raise up to ₹1,300 crore. The decision was taken on September 9, 2026, and the company positioned the issue as a specific fundraising route rather than a broader mandate to raise equity or other securities. The company said the rights issue will be offered to eligible equity shareholders on a rights basis. Natco Pharma also approved the draft letter of offer for the issue, indicating the process is moving into the documentation and regulatory stage. The final number of shares to be issued and the issue price are yet to be determined. The record date that will decide shareholder eligibility has also not been announced.

What the company has disclosed so far

Natco Pharma said the fundraising is proposed through equity shares with a face value of ₹2 each. The company stated that the issue price per rights equity share is yet to be finalised, and it will include a premium. The entitlement ratio is also pending and was presented as a placeholder linked to the record date. While the total fundraise is capped at ₹13,000 million (₹1,300 crore), the actual proceeds will depend on the final terms and subscription. Natco Pharma’s existing equity shares are listed on both BSE and NSE. The company said it has received in-principle approvals from NSE and BSE for listing of the rights equity shares.

Fund-Raising Committee constituted

To oversee the transaction, the board constituted a Fund-Raising Committee comprising Chairman V.C. Nannapaneni, Rajeev Nannapaneni, and P.S.R.K. Prasad. The committee structure signals that key decisions on structure and execution will be handled through a dedicated internal group. This includes steps such as finalising the issue price, deciding the number of shares, and coordinating on timelines and documentation. The committee will also typically interface with intermediaries and manage compliance steps connected with the issue.

Use of proceeds: debt, R&D, and inorganic growth

Natco Pharma stated that the net proceeds are proposed to be used across three main buckets, subject to limits under SEBI ICDR Regulations. A portion of the proceeds is proposed to be used for pre-payment or repayment of certain outstanding borrowings, quantified at ₹8,105 million. Another ₹1,100 million is proposed to fund part of the expenditure for research and development initiatives, including employee costs for the R&D team. The remaining proceeds are proposed to be used for inorganic growth through unidentified acquisitions and other strategic initiatives, as well as general corporate purposes. The company did not name any acquisition targets in the disclosure.

Issue mechanics: ASBA-only payments and entitlements in demat

Natco Pharma stated that payments for application forms must be made only through the ASBA facility. This means applications will route through banks and the block-in-account mechanism rather than cheque-based payments. The company also said it has opened a separate demat suspense escrow account for crediting Rights Entitlements. The opening and closing dates of the issue were not specified and were indicated as to be announced later. The disclosure also noted that the record date is yet to be decided, which will be important for shareholders tracking eligibility.

Share capital context and listing status

Natco Pharma disclosed that it currently has an issued, subscribed, and paid-up share capital of 179,109,870 equity shares. Post the rights issue, the total number of equity shares outstanding is expected to change, but the post-issue figure was not provided. The company reiterated that its equity shares are listed on BSE and NSE, and that it has obtained in-principle approvals from both exchanges for listing of the rights equity shares. These approvals are a procedural step that supports the issuance and subsequent trading of the newly issued shares.

Snapshot: the key facts in one place

Market context: price and market cap data disclosed

The disclosure also included market data points, placing Natco Pharma at a market capitalisation of ₹14,829 crore with a current price of ₹828. These figures provide context on the company’s size in the listed market as it approaches the rights issue. A rights issue structure typically targets existing shareholders, and the eventual subscription levels can depend on the final pricing and entitlement ratio. Natco Pharma has not disclosed the premium level or any indicative price range at this stage. Investors tracking the issue will likely focus on the pricing, the record date, and the final offer timetable once announced.

Business backdrop mentioned by the company

Natco Pharma’s international business was described as focusing on Para IV filings. The company also said it plans to expand into emerging markets such as MENA, ASEAN, and LATAM. While these points are not directly tied to the rights issue timetable, they provide context for the stated intention to fund R&D initiatives and inorganic growth. The company’s disclosure did not connect the proposed acquisitions to specific geographies or therapy areas.

Why the rights issue structure matters

Natco Pharma explicitly described the rights issue as replacing an earlier broader mandate to raise equity or other securities. This narrows the fundraising route to a rights-based offering to existing shareholders rather than a more flexible set of instruments. For shareholders, the key operational milestones now are the record date, the entitlement ratio, the issue price, and the opening and closing dates. The company has already disclosed that the issue price will include a premium, but the actual level will be decided later.

Conclusion

Natco Pharma’s board has approved a ₹1,300 crore rights issue and cleared the draft letter of offer, with a committee in place to steer execution. The company has also outlined intended use of proceeds across borrowings repayment, R&D spending, and inorganic growth. The next set of disclosures will be the record date, entitlement ratio, issue price, and the detailed schedule for opening and closing of the issue.